ALK and lung cancer: In general, failure to achieve tumor growth inhibition by crizotinib could be due to mutations in the ALK kinase domain that effect inhibitor binding or increase ALK catalytic activity or ALK gene amplification both observed in therapy-resistant lung cancer [45].